The correspondence, published on 16 September 2026, responds directly to the CaRe feasibility study, a head and neck cancer rehabilitation trial published earlier in the same journal in June 2026 by Sheill and colleagues. Feasibility studies occupy a crucial niche in clinical research. They test whether a trial can actually be done: whether patients will enrol, whether clinicians can deliver the intervention consistently, whether outcome measures are tolerable and interpretable, and whether attrition stays within acceptable limits. The CaRe study did exactly this work for a structured rehabilitation programme in head and neck cancer, laying the groundwork that larger definitive trials require.

Yet Abou-Bakr and Hassanein contend that a trial can pass every feasibility benchmark and still fail to answer the questions that matter most to patients, if it treats all head and neck cancer survivors as a single homogeneous group. Their central argument is that lymphoedema is not a minor comorbidity to be averaged out in randomisation; it is a distinct clinical entity that changes what rehabilitation should look like, what outcomes are realistic, and how success should be measured. Pooling patients with and without lymphoedema, they suggest, risks diluting treatment effects and obscuring the very signals that a definitive trial is designed to detect.

The clinical case for stratification rests on a growing body of evidence about what head and neck lymphoedema actually does to patients. A 2026 systematic review by Gaitatzis and colleagues in the Journal of Cancer Survivorship examined patient-reported outcome measures and physical function following head and neck lymphoedema and documented the breadth of its impact. Unlike limb lymphoedema, which is visible and relatively straightforward to measure with circumference or volume techniques, lymphoedema in the head and neck region affects structures that govern speech, swallowing, breathing, and appearance. Internal lymphoedema, involving the pharynx and larynx, can be invisible from the outside while profoundly impairing function.

The burden extends well beyond physical symptoms. Research by Starmer and colleagues, published in Supportive Care in Cancer in 2023, captured the patient perspective on head and neck lymphoedema and quality of life, revealing how swelling reshapes identity, social interaction, and emotional wellbeing. A 2024 study by Arends and colleagues in the journal Cancers added further weight, showing that lymphoedema and trismus, the restriction of jaw opening that frequently accompanies treatment, have a measurable impact on body image and quality of life after head and neck cancer. For a population already coping with disfigurement, altered speech, and compromised swallowing, lymphoedema compounds the challenge of returning to a recognisable life.

Against this backdrop, the evidence base for treating head and neck lymphoedema remains strikingly thin. A 2025 systematic review by de-la-Cruz-Fernández and colleagues in Supportive Care in Cancer assessed randomised controlled trials of physical therapy interventions for lymphoedema management in this population and found the available trials limited in number and scope. This scarcity is precisely why feasibility work such as the CaRe study matters, and equally why the field cannot afford to design its definitive trials carelessly. If the few large trials that eventually emerge fail to account for lymphoedema status, an entire generation of rehabilitation evidence may be built on foundations too heterogeneous to support firm conclusions.

The argument for lymphoedema-stratified trial design has technical dimensions that go beyond simple subgroup analysis. Stratification in randomised trials means that patients are grouped by a key prognostic characteristic before randomisation, ensuring that treatment and control arms are balanced for that characteristic. In the context of head and neck cancer rehabilitation, stratifying by lymphoedema presence, severity, or type, external versus internal, would allow investigators to estimate whether rehabilitation produces different benefits in patients whose lymphatic systems have been compromised. It would also permit pre-specified subgroup analyses that are powered and planned from the outset, rather than the underpowered post hoc explorations that have historically plagued rehabilitation research.

Measurement is another pillar of the argument. Trials that ignore lymphoedema may choose outcome instruments that are insensitive to the changes that matter most to affected patients. The systematic review by Gaitatzis and colleagues highlighted the state of patient-reported outcome measures in this space, and the correspondence implicitly raises the question of whether generic quality-of-life instruments can capture the specific distress of facial and neck swelling, or whether lymphoedema-specific measures should be embedded in trial design. A rehabilitation programme might improve general physical function while leaving a patient’s lymphoedema-related body image concerns untouched, a result that a poorly designed trial would misread as partial success rather than a targeted failure.

The broader context of head and neck cancer survivorship strengthens the case further. Studies of rehabilitation needs, including work by Karampela and colleagues published in Frontiers in Oncology in 2021, have documented gaps between what patients require and what services deliver, while a 2025 systematic review by Bernstein and colleagues catalogued the social impacts of treatment and rehabilitation in this population. Head and neck cancer survivors face some of the highest rates of depression, social withdrawal, and functional impairment in oncology, and rehabilitation is the discipline charged with restoring what treatment takes away. Designing rehabilitation trials that reflect the true clinical heterogeneity of the population is therefore not a methodological nicety; it is a prerequisite for evidence that translates into meaningful care.

Abou-Bakr and Hassanein’s correspondence, written without specific funding and with no declared competing interests, functions as a call to action for trialists in supportive and rehabilitative cancer care. The message is that the field has demonstrated it can run rehabilitation studies in head and neck cancer; the CaRe feasibility study and its predecessors have answered the operational questions. The next step demands more ambition: definitive trials in which lymphoedema is not an afterthought but a design principle, with stratified randomisation, lymphoedema-sensitive outcome measures, and analyses planned to reveal which patients benefit most from which interventions. For the growing population of head and neck cancer survivors living with swelling that affects how they speak, swallow, and see themselves in the mirror, the difference between a generic rehabilitation trial and a lymphoedema-stratified one could ultimately determine whether the evidence that guides their care is sharp enough to help them.

Subject of Research: Lymphoedema-stratified rehabilitation trial design in head and neck cancer survivorship

Article Title: Beyond feasibility: the case for lymphoedema-stratified rehabilitation trials in head and neck cancer

Article References: Abou-Bakr, A., & Hassanein, F. E. A. (2026). Beyond feasibility: the case for lymphoedema-stratified rehabilitation trials in head and neck cancer. Supportive Care in Cancer, 34(10), Article 977. https://doi.org/10.1007/s00520-026-11222-8

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11222-8

Keywords: head and neck cancer, lymphoedema, cancer rehabilitation, clinical trial design, stratification, feasibility study, quality of life, supportive care, physical therapy, trismus, patient-reported outcomes, cancer survivorship

The trial, led by Mengyuan Li and colleagues at the University of Southern Queensland and partner institutions in Australia and China, enrolled 108 women who had completed chemotherapy for early-stage breast cancer between one month and three years earlier. Each participant reported at least moderate levels of fatigue, sleep disturbance and depression, scoring four or higher on a standard 0-to-10 rating scale. The women were randomly allocated in equal numbers to one of three groups: a true self-acupressure group, a sham self-acupressure group, or a usual care group. Ninety-three participants completed the study, with 31 in each arm, and the retention rate of 86 percent was notably strong for a trial of this length and population.

The intervention itself was elegantly simple. Women in the true acupressure group were trained in a 20-minute face-to-face session to apply firm pressure to eleven acupoints, seven of them bilateral, chosen for their traditional and emerging scientific relevance to fatigue, sleep and mood. These included well-known points such as Zusanli (ST36) on the lower leg, Neiguan (PC6) on the forearm, Shenmen (HT7) on the wrist, and Yintang (EX-HN3) between the eyebrows. Each point was stimulated for two minutes, adding up to a daily 36-minute practice continued for seven weeks. Participants in the sham group followed an identical regimen but pressed eleven non-acupoints located one to three centimetres away from the real points and deliberately off the classical meridians. Because both groups performed an active, plausible technique, neither the participants nor the self-rated outcome assessments could distinguish true from sham treatment, providing a rigorous test of whether acupressure’s benefits depend on stimulating specific points or simply on the ritual of self-care.

The results were unambiguous. Using a sophisticated statistical approach—generalised estimating equations with covariate selection guided by penalised regression—the researchers found significant group-by-time interactions for every clinical outcome. The true self-acupressure group showed substantially greater reductions in the composite symptom cluster score than both comparison groups, not only at the end of the seven-week intervention but also at the twelve-week follow-up, with large standardised effect sizes reaching as high as 2.33 against usual care. Crucially, the benefits were sustained: the advantage over the sham group actually grew over time, suggesting that continued practice deepened the therapeutic effect rather than fading like a placebo response.

At the level of individual symptoms, the pattern was equally compelling. Sleep disturbance, measured with the Pittsburgh Sleep Quality Index, and depression, measured with the Hospital Anxiety and Depression Scale, both improved significantly more in the true acupressure group than in either comparison group at both assessment points. Fatigue, measured with the Brief Fatigue Inventory, showed a large advantage over usual care throughout, while the difference between true and sham acupressure reached statistical significance only at the twelve-week follow-up. Quality of life, assessed with the Functional Assessment of Cancer Therapy-Breast instrument, rose markedly in the true acupressure group, with the gap over the sham group widening from a non-significant trend at week seven to a highly significant difference by week nineteen.

One of the most scientifically interesting findings concerns the sham group itself. Women who pressed non-acupoints also fared significantly better than those receiving usual care, with moderate effect sizes. The authors attribute this to placebo and psychosocial mechanisms: the strong desire for symptom relief, positive expectations, and the act of actively engaging in a daily self-care ritual can all modulate symptom perception through genuine psychological and physiological pathways. This does not diminish the value of the true intervention—whose effects were consistently larger and more durable—but it does highlight how much of symptom management in cancer survivorship may be harnessed through expectation and self-efficacy. The trial’s design, following a sham-controlled structure refined through an earlier phase II pilot study, allowed the researchers to separate these non-specific effects from the specific benefits of stimulating authentic acupoints.

Why might pressing specific points on the body influence fatigue, sleep and mood at all? The prevailing biological explanation for this symptom cluster is cytokine-induced sickness behaviour: cancer treatments trigger persistent low-grade inflammation, and pro-inflammatory signalling molecules act on the brain to produce the lethargy, sleep disruption and low mood that survivors describe. Non-pharmacological interventions such as exercise, acupuncture and acupressure have been shown in prior research to reduce circulating pro-inflammatory cytokines, offering a plausible mechanistic bridge. The trial’s authors acknowledge, however, that they did not directly measure cytokines in this study, leaving the precise biological pathway an open question for future work.

Safety and cost are where the findings become genuinely striking for clinical practice. Not a single adverse event was reported across the entire trial, a stark contrast to acupuncture, which carries small risks of infection and bruising due to its invasive nature, and to pharmacological approaches, which raise concerns about drug interactions in patients already on complex regimens. The economic picture was similarly favourable: during the trial, only one participant in the true acupressure group and one in the usual care group used healthcare resources for symptom relief, with total costs of 931.06 and 2,247.44 yuan respectively, while the only direct intervention cost was a one-off 2,879 yuan for producing instructional videos. The researchers caution that these numbers are too sparse for a formal cost-effectiveness analysis, but the direction of the data is hard to ignore.

The trial was not without limitations. All outcomes relied on self-reported questionnaires, which, although well-validated, are inherently subjective; the authors recommend that future studies incorporate objective measures such as actigraphy or inflammatory biomarkers. The composite cluster score assumed equal weighting of the three symptoms, and adherence to the full 49-day practice schedule was challenging, with only about 28 percent of the true acupressure group completing every day. Yet even partial adherence produced large effects, and the researchers suggest that real-world implementation could allow individualised adjustments to session length based on each woman’s energy and symptom burden.

The implications reach well beyond breast cancer. With more than 53 million people worldwide now living five or more years past a cancer diagnosis, accessible, self-managed strategies for the lingering burden of survivorship are urgently needed. Cognitive behavioural therapy demands multiple sessions with trained therapists; exercise programmes can be exhausting for women already depleted by fatigue. Self-acupressure, by contrast, requires only a short training, can be practised anywhere at any time, and costs almost nothing once learned. The authors argue that the intervention could be readily integrated into routine survivorship care and primary healthcare settings, particularly where professional resources are scarce. As the first fully powered phase III trial to demonstrate sustained, cluster-level benefits of self-acupressure in breast cancer survivors, the study transforms an ancient technique into a modern, evidence-based prescription—one that patients can literally hold in their own hands.

Subject of Research: Self-acupressure for managing the fatigue-sleep disturbance-depression symptom cluster in breast cancer survivors

Article Title: Effects of self-acupressure on the fatigue-sleep disturbance-depression symptom cluster in breast cancer survivors: a phase III randomised controlled trial

Article References: Li, M., Kwok, W. H., Wang, T., Deng, R., Wang, H., Yao, L., Deravin, L., Yang, L., Tian, X., & Tan, J.-Y. B. (2026). Effects of self-acupressure on the fatigue-sleep disturbance-depression symptom cluster in breast cancer survivors: a phase III randomised controlled trial. Supportive Care in Cancer, 34(10), Article 981. https://doi.org/10.1007/s00520-026-11155-2

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11155-2

Keywords: self-acupressure, breast cancer survivors, symptom cluster, fatigue, sleep disturbance, depression, randomised controlled trial, quality of life, traditional Chinese medicine, cancer survivorship, non-pharmacological intervention, placebo effect

The study took a mixed-methods approach, pairing quantitative questionnaires with open-ended questions that invited participants to describe their experiences in their own words. Each student completed the WHOQOL-BREF-ID, a brief quality-of-life instrument adapted for people with intellectual disabilities, and the WHOQOL-DIS, a module developed by the World Health Organization specifically to assess quality of life in people with disabilities. These instruments capture domains such as physical health, psychological well-being, social relationships, and the environment, along with disability-specific dimensions like autonomy, social inclusion, and discrimination. The researchers then analyzed the quantitative data using nonparametric statistics, a choice appropriate for the skewed distributions and modest sample sizes typical of this kind of research, while the written responses underwent reflexive thematic analysis, a qualitative technique in which researchers systematically identify recurring patterns of meaning while remaining aware of how their own perspectives shape interpretation.

One of the most striking quantitative findings concerned students with co-occurring autism spectrum disorder and ADHD. These students reported significantly poorer psychological well-being than students with autism alone, and lower social inclusion than students with ADHD alone. The finding matters clinically because autism and ADHD frequently co-occur, and research has repeatedly suggested that the combination can amplify executive-function demands, sensory challenges, and social difficulties beyond what either condition produces on its own. The Brazilian results, though the authors describe them as preliminary, hint that this doubly neurodivergent subgroup may be slipping through the cracks of support systems organized around single diagnostic categories. A university that offers autism-specific services and separate ADHD accommodations may not be equipped to serve students who need both at once, in an integrated and individualized way.

Socioeconomic status emerged as a second powerful predictor of how students fared. Using the classification system of the Brazilian Association of Research Companies, the team found that students from higher socioeconomic backgrounds reported better environmental quality of life, greater social inclusion, and higher disability-related quality of life. In practical terms, money appears to buffer the barriers that universities and cities impose: access to private psychological care, quieter housing, reliable transportation, assistive technology, and the freedom to reduce course loads without financial catastrophe. In a country with steep educational inequality, the finding suggests that neurodivergent students from poorer families face a double disadvantage, contending simultaneously with the structural obstacles of their institutions and the material constraints of their households.

The qualitative half of the study gave those numbers a human voice. Across the open-ended responses, four major challenges recurred: insufficient institutional support, overwhelming academic demands, stigma, and barriers to social participation. Students described support offices that existed on paper but delivered little in practice, professors who were unaware of or skeptical toward accommodations, and assessment formats that penalized the very cognitive differences, such as difficulties with timed written exams or multi-step instructions, that defined their neurodivergence. Socially, many reported feeling invisible or misunderstood on campus, excluded from study groups and informal networks that are often crucial to academic persistence. These accounts align with a growing international literature showing that the transition to higher education is a period of heightened vulnerability for neurodivergent students, who frequently arrive without the scaffolding that schools and families provided earlier in their lives.

Importantly, the researchers did not frame their participants solely as a population of deficits. The qualitative analysis also surfaced students’ strengths and their concrete recommendations for change. Participants described capacities such as intense focus on topics of interest, creative problem-solving, and distinctive perspectives that enriched their coursework. Their proposals for more accessible universities included clearer and earlier communication about accommodations, training for faculty, sensory-friendly physical spaces, flexible assessment options, and mentoring programs that connect neurodivergent students with one another. The study’s framing reflects a neurodiversity-affirming lens, which treats neurological variation as a natural feature of the human population rather than a defect to be corrected, and which asks institutions to adapt to students rather than requiring students to mask their differences to survive.

The authors are candid about the limits of their perspective. In an unusual positionality statement, they note that they are speech-language pathology and educational psychology researchers and clinicians based in Brazil, that none of them identify as neurodivergent, and that this may have influenced their interpretation of participants’ lived experiences. To mitigate that risk, they engaged in reflexive analysis throughout the project, checked for alignment between the quantitative and qualitative findings, and drew on existing scholarship produced by and with neurodivergent people. They also acknowledge that their status as university-based researchers may have shaped how openly students disclosed their experiences. This kind of transparency is increasingly expected in high-quality qualitative research, and it gives readers a framework for weighing the findings rather than accepting them uncritically.

Methodologically, the study has the constraints typical of cross-sectional designs. With 80 participants recruited at a single point in time, it can describe associations but cannot establish causation; the link between socioeconomic status and quality of life, for example, could run through many unmeasured pathways. The sample, drawn from Brazilian higher education institutions, may not represent neurodivergent students who never reached university, a group likely facing even greater barriers. The WHOQOL instruments, while validated, were not designed specifically for neurodivergent populations without intellectual disability, and self-report measures in any population are subject to mood and recall effects. The authors present the co-occurring ASD-ADHD findings as preliminary and call for larger, longitudinal studies that could track how quality of life changes across the university trajectory and identify which interventions actually help.

Even with those caveats, the implications are substantial. The study argues that the barriers neurodivergent students face extend well beyond the academic accommodations that most inclusion policies address, reaching into institutional culture, social life, and the physical and informational accessibility of the campus itself. In Brazil, where federal legislation guarantees educational inclusion but implementation varies widely between institutions, the findings offer an evidence base for comprehensive, neurodiversity-affirming strategies rather than piecemeal fixes. For universities everywhere, the message is uncomfortable but clear: admitting neurodivergent students is not the same as including them, and the students who struggle most may be those whose needs do not fit neatly into a single diagnostic box. As neurodivergent enrollment continues to grow, the institutions that thrive will be those that listen to students’ own accounts of what helps, and that treat accessibility as a property of the whole environment rather than a service delivered to a few.

Subject of Research: Quality of life and academic experiences of neurodivergent university students in Brazilian higher education

Article Title: Quality of life and university experiences of neurodivergent students in Brazilian higher education

Article References: Tsalamatas, I. S., Ferreira, H. A., Nosari Santos, M. E., Cardilli-Dias, D., & Molini-Avejonas, D. R. (2026). Quality of life and university experiences of neurodivergent students in Brazilian higher education. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08622-9

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08622-9

Keywords: neurodivergence, autism spectrum disorder, ADHD, quality of life, higher education, Brazil, WHOQOL, social inclusion, stigma, institutional support, mixed methods, neurodiversity

The study, conducted by a team of clinicians at the Affiliated Hospital of North Sichuan Medical College in Nanchong, China, enrolled 120 patients who had been transferred from the ICU to general wards between June 2025 and September 2025 and who reported clinically significant sleep disturbances. The trial was prospectively registered with the Chinese Clinical Trial Registry, and all participants provided written informed consent under ethics approval from the hospital. Participants were randomly assigned in equal numbers to two groups, a design that allows researchers to isolate the specific effect of the new therapy from the benefits of routine care.

The control group received what many hospitals would consider standard treatment: the hypnotic drug eszopiclone, a non-benzodiazepine sedative commonly prescribed for insomnia, combined with routine sleep hygiene education, the practical advice about caffeine, light exposure, and bedtime routines that clinicians typically offer. The intervention group received the same pharmacological foundation but added a three-month program of internet-based cognitive behavioral therapy, or ICBT. This approach adapts the well-established principles of in-person cognitive behavioral therapy for insomnia to a digital format, allowing patients to work through therapeutic modules online at their own pace while submitting sleep diaries that track their progress.

Cognitive behavioral therapy for insomnia differs fundamentally from sleeping pills in how it targets the disorder. Rather than acting on brain chemistry to induce drowsiness, it works on the behaviors and thought patterns that sustain sleeplessness: irregular sleep schedules, excessive time in bed awake, catastrophic beliefs about the consequences of a bad night, and conditioned arousal in the bedroom. For ICU survivors, these mechanisms are particularly relevant, because the abnormal environment of critical care, with its constant light, noise, and frequent monitoring, can entrench deeply disrupted sleep patterns that then persist through learned association long after the physical threats have resolved.

The researchers assessed outcomes at three time points: baseline before treatment began, immediately after the three-month intervention, and again one month later, four months after baseline. They used a battery of validated instruments, including the Pittsburgh Sleep Quality Index and the Insomnia Severity Index to measure sleep, the Hamilton Anxiety and Depression Rating Scales to capture mood symptoms, and the 36-Item Short Form Health Survey to evaluate overall quality of life. This combination allowed the team to examine not just whether patients slept better, but whether the therapy rippled outward into their emotional and functional recovery.

The results were strikingly consistent for most outcomes. At both the end of the intervention and at follow-up, the group receiving ICBT showed significantly greater improvements than the control group in sleep quality, insomnia severity, depressive symptoms, and quality of life scores. The only exception was anxiety: the between-group difference in Hamilton Anxiety scores was not statistically significant immediately after the three-month program, but emerged at the one-month follow-up, suggesting that the emotional benefits of the therapy may take longer to consolidate than its direct effects on sleep.

Perhaps the most clinically consequential finding concerned medication. The rate of reduction in sleep medication was significantly higher in the intervention group than among patients receiving drugs alone. For a population already burdened by the pharmacological intensity of critical care, where sedatives, analgesics, and other agents accumulate during an ICU stay, the prospect of tapering hypnotic medication while maintaining or improving sleep represents a substantial advantage. It points toward a model of care in which digital therapy does not merely complement drugs but gradually replaces them.

The trial also provided encouraging data on adherence, often the Achilles heel of digital health interventions. Patients in the ICBT group showed good completion rates for the online modules and submitted sleep diaries reliably, while the control group demonstrated good acceptance of education and compliance with medication. An exploratory analysis of the intervention group’s diary data revealed significant within-group improvements over time in three objective-sounding sleep parameters: sleep efficiency, the proportion of time in bed actually spent asleep; sleep onset latency, how long it takes to fall asleep; and wake after sleep onset, the amount of time spent awake during the night. These are precisely the metrics that insomnia clinicians target most directly.

The significance of the study lies partly in its population. Post-intensive care syndrome, the cluster of physical, cognitive, and psychological impairments that follows critical illness, has become a major focus of critical care medicine, yet sleep disturbance within it remains under-treated. Traditional face-to-face cognitive behavioral therapy is effective for insomnia but requires trained therapists, multiple clinic visits, and considerable time, resources that are scarce for patients navigating recovery from critical illness. An internet-based format sidesteps many of these barriers, delivering structured therapeutic content to patients who may have limited mobility, live far from specialist services, or feel too fragile for frequent hospital trips.

The trial has limits worth noting. It was conducted at a single hospital over a concentrated recruitment window, and the follow-up extended only one month beyond the end of treatment, leaving longer-term durability an open question. The sleep diary findings were exploratory and drawn from within-group comparisons rather than the randomized contrast. Even so, the pattern of results, sustained improvements in sleep, mood, and quality of life, alongside reduced reliance on hypnotic medication, offers a compelling case that digital cognitive behavioral therapy deserves a place in the aftercare of ICU survivors. As hospitals worldwide grapple with the growing population of critical illness survivors, this study suggests that the most effective prescription for their broken sleep may arrive not in a pill bottle, but through a screen.

Subject of Research: Efficacy of internet-based cognitive behavioral therapy for sleep disturbances in ICU survivors

Article Title: A randomized controlled trial of internet-based cognitive behavioral therapy for sleep disturbances in ICU survivors

Article References: Xia, Y., Yang, J., Ding, X., Lai, X., Yong, N., Liu, H., Ma, Y., & Cui, L. (2026). A randomized controlled trial of internet-based cognitive behavioral therapy for sleep disturbances in ICU survivors. BMC Psychology. https://doi.org/10.1186/s40359-026-05702-z

Image Credits: AI Generated

DOI: 10.1186/s40359-026-05702-z

Keywords: internet-based cognitive behavioral therapy, ICU survivors, sleep disturbances, insomnia, randomized controlled trial, eszopiclone, post-intensive care syndrome, sleep quality, depression, quality of life, sleep hygiene, digital health

The research team, led by Yang Wang and corresponding author Haibo Xiong, enrolled 214 children with myopia and divided them into two developmental bands: 116 preschool children aged 3 to 6 years and 98 school-aged children aged 7 to 12 years. Every child underwent comprehensive refractive testing in 2022 and was then fitted with full-correction single-vision spectacles, meaning lenses that fully compensate for the child’s measured refractive error rather than deliberately under-correcting it. One year later, the researchers repeated the refractive measurements and administered validated quality-of-life instruments to capture how the children and their families were faring.

The optical side of the study produced a clear and clinically meaningful pattern. Myopia, measured as spherical equivalent refraction, progressed faster in the older group. Children aged 3 to 6 years showed an average annual increase in myopia of 0.58 diopters, with a standard deviation of 0.67 diopters per year, while children aged 7 to 12 years progressed at 0.99 diopters per year, with a standard deviation of 0.57 diopters. The difference between the two age groups was statistically significant, with a P value below 0.001. In practical terms, the school-aged children lost refractive ground roughly 70 percent faster than their preschool counterparts, a finding that aligns with the widely observed acceleration of myopia during the early school years when near work intensifies and outdoor time often declines.

Multiple linear regression analysis helped the team disentangle which variables independently drove the annual change in spherical equivalent. Three factors emerged: the child’s age group, the degree of myopia at baseline, and the amount of time spent on outdoor activity. This trio of predictors is consistent with the broader scientific understanding of myopia as a condition shaped by both the eye’s intrinsic growth trajectory and environmental exposure, particularly time spent outdoors, which is thought to protect against axial elongation of the eyeball through light-driven retinal signaling. The regression result reinforces the message that outdoor time remains an independent, modifiable lever even after spectacles are prescribed.

The quality-of-life findings are where the study delivers its most emotionally resonant punch. The researchers used two established pediatric instruments: the PedsQL 4.0 Generic Core Scales, completed to assess the children’s health-related quality of life, and the PedsQL 2.0 Family Impact Scale, administered to the parents to measure how the child’s condition affected family functioning. After one full year of wearing full-correction single-vision spectacles, the total PedsQL score of the school-aged children rose significantly, from a median of 78.56 with an interquartile range of 73.53 to 84.06 at baseline to 86.63 with an interquartile range of 78.22 to 91.78 at follow-up, a difference the authors report as statistically significant at P equals 0.001.

Parents reported improvements as well, and notably in both age groups. In the preschool group, the median total parental survey score climbed from 75.11, with an interquartile range of 71.73 to 82.86, to 82.15, with an interquartile range of 75.90 to 89.36, a statistically significant rise at P equals 0.007. In the school-aged group, the parental median rose from 73.87, with an interquartile range of 67.45 to 80.05, to 80.20, with an interquartile range of 73.60 to 83.07, also significant at P equals 0.011. The fact that the Family Impact Scale improved in both cohorts suggests that the benefits of clear vision ripple outward through the household, easing parental worry, reducing functional burdens, and improving the emotional texture of family life around a child’s vision problem.

Why would simply wearing the right glasses move quality-of-life scores so substantially? The mechanisms are plausibly layered. Uncorrected or under-corrected myopia forces children to squint, sit close to screens and books, and strain to follow classroom activity, all of which can generate headaches, fatigue, and frustration. Blurred distance vision can also interfere with sports, social interaction, and the visual feedback children need for confident navigation of their environment. Full correction restores retinal image clarity, which supports visual comfort and participation in the activities that dominate childhood. For school-aged children in particular, the classroom is the arena where uncorrected refractive error exacts its heaviest toll, which may explain why their PedsQL gains were the most pronounced in the study.

The study’s design deserves a note of appreciation from a methodological standpoint. As a prospective observational cohort, it followed the same children over time rather than comparing separate groups, which strengthens the temporal logic linking correction to improvement. The use of validated, age-appropriate instruments, the PedsQL 4.0 for child-reported quality of life and the PedsQL 2.0 for family impact, grounds the subjective outcomes in standardized scoring. Reporting medians with interquartile ranges, as the authors did, is appropriate for score distributions that often skew, and the consistent statistical significance across child and parent reports in both age bands lends the findings internal coherence. At the same time, the observational nature means the results describe associations over time within a treated cohort rather than the effect of glasses versus no glasses, since all children received correction and no untreated control group was followed.

The clinical implications are nonetheless direct. Myopia is escalating into a global public health concern, with prevalence rising sharply in East Asia and across many urban populations, and earlier onset predicts higher lifetime risks of pathological complications such as retinal detachment and myopic maculopathy. This study adds an important dimension to the case for early detection and full correction: the benefit is not confined to visual acuity charts but extends to how children feel and function and how families experience the child’s condition. It also pushes back against a lingering folk belief in some communities that wearing full-prescription glasses makes children’s eyes lazy or worsens myopia. The data here show myopia progressing, as expected, in both age groups despite full correction, but the children’s reported wellbeing improved, not deteriorated, over the year of wear.

For parents, the practical takeaways are straightforward. Schedule regular refractive screenings in the preschool years, because myopia can begin before a child can articulate blurred vision, and the faster progression seen in school-aged children argues for catching it early. Embrace full correction when an eye-care professional prescribes it, since the evidence here links complete optical correction with improved quality of life. And protect outdoor time, which the regression analysis flagged as an independent factor in slowing the annual march of myopia. A child’s glasses, this research suggests, are not merely a visual aid but an intervention with the power to lift the everyday life of an entire family, one clear image at a time.

Subject of Research: Effect of spectacle correction of myopia on health-related quality of life in children aged 3 to 12 years

Article Title: Effect of refractive correction of myopia on health-related quality of life among children aged 3–12 years: a prospective observational cohort study

Article References: Wang, Y., Pi, L., Ouyang, L., Chen, S., Chen, K., & Xiong, H. (2026). Effect of refractive correction of myopia on health-related quality of life among children aged 3–12 years: a prospective observational cohort study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07733-2

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07733-2

Keywords: myopia, children, refractive correction, spectacles, quality of life, PedsQL, pediatrics, vision disorders, school age, preschool age, outdoor activity, cohort study

The study team, led by researchers from Chengdu Xinjin District People’s Hospital and Sichuan Provincial People’s Hospital, enrolled patients diagnosed according to the FIGO 2018 staging criteria who had undergone chemoradiation, chemotherapy alone, radiation alone, targeted therapy, or no anticancer treatment at all. By drawing on electronic medical records alongside structured patient questionnaires, the investigators assembled a detailed picture of each patient’s disease status, treatment history, and symptom profile. Fatigue was assessed using validated multidimensional instruments, allowing the team to distinguish mild exhaustion from the moderate-to-severe syndrome that most interferes with daily functioning. This dual-source data approach matters because fatigue is notoriously underreported in routine oncology visits, often dismissed by both patients and clinicians as an inevitable consequence of cancer treatment rather than a treatable condition in its own right.

When the researchers ran their multivariate logistic regression, seven independent factors emerged as significant predictors of moderate-to-severe fatigue. Disease stage carried a P value of 0.001, meaning that women with more advanced tumors were substantially more likely to report debilitating exhaustion. Performance status, measured on the Eastern Cooperative Oncology Group scale, was also significant at P = 0.003, reflecting the intuitive but clinically important observation that patients already weakened by their illness are more vulnerable to fatigue. Cancer pain, anemia, and poor appetite each showed even stronger associations, all with P values below 0.001, painting a picture of fatigue as a synergistic symptom cluster rather than an isolated complaint. Perhaps most thought-provoking was the finding that proactive clinician attention to fatigue complaints was independently associated with lower rates of severe fatigue, with P = 0.042, suggesting that the quality of supportive care itself shapes patient outcomes.

The biological logic behind these associations is well supported by the broader literature. Advanced tumor burden drives systemic inflammation, releasing cytokines such as tumor necrosis factor that act directly on the central nervous system to produce the sensation of exhaustion. Anemia reduces oxygen delivery to tissues, compounding the physical cost of every activity, while poor appetite accelerates the catabolic spiral of cancer cachexia, a syndrome whose molecular basis has been increasingly mapped in recent years. Pain disrupts sleep and depletes the physical and psychological reserves patients need to cope with treatment. In other words, the Chinese findings align with a mechanistic model in which fatigue is the downstream product of multiple converging physiological insults, each of which represents a potential point of intervention.

The most eye-catching result, however, concerned Buzhong-Yiqi, a classical herbal formula first codified in the Jin-Yuan dynasty treatises on the spleen and stomach, which in Traditional Chinese Medicine theory is thought to tonify qi and address patterns of internal injury. In the raw comparison between patients who received the formula and those who did not, the BZYQ group showed meaningfully lower symptom scores on independent-sample t-tests and Chi-squared comparisons. But observational data of this kind are always vulnerable to confounding: clinicians may simply prescribe the formula to patients who are less sick to begin with, or conversely to those with more resources and better overall care. To address this, the researchers turned to a statistical technique called propensity-score weighting.

Propensity-score weighting is a method borrowed from causal inference that attempts to simulate the balance of a randomized trial using observational data. Each patient receives a score representing the probability, given her measured baseline characteristics, of having been assigned to the BZYQ group. By weighting patients according to the inverse of these probabilities, the technique creates pseudo-populations in which treated and untreated groups are statistically comparable across the measured covariates, allowing the treatment effect estimate to be freed from the distortion introduced by non-random prescribing. After applying this weighting, the association between BZYQ use and fatigue remained robust: patients in the treated group had a 68.3 percent reduction in the odds of moderate-to-severe cancer-related fatigue, corresponding to an odds ratio of 0.317 with a P value below 0.001.

It is crucial to interpret this number with appropriate scientific caution. This was a retrospective, single-region observational study of 144 patients, not a randomized controlled trial, and propensity-score methods can only adjust for confounders that were measured and recorded. Unmeasured factors, such as differences in social support, adherence, nutritional status, or general health consciousness, could still explain part of the observed association. The authors themselves are careful to frame the finding as preliminary evidence, describing the result as real-world observational data that provides clues for further exploration of the formula’s application value in fatigue management rather than proof of efficacy. Previous systematic reviews of Chinese herbal medicine for cancer-related fatigue have noted the scarcity of high-quality randomized trials, making rigorous prospective testing the obvious next step.

Even setting the herbal question aside, the study carries a clear and actionable message for oncology practice. Cancer-related fatigue is recognized in clinical practice guidelines from both the National Comprehensive Cancer Network and the European Society for Medical Oncology as a syndrome deserving systematic screening and management, yet it remains chronically underassessed in busy clinics. The finding that proactive clinician attention independently predicts better fatigue outcomes suggests that simply asking about exhaustion, taking it seriously, and intervening early may itself change the trajectory of the symptom. The authors argue that fatigue screening should be built into routine care for cervical cancer patients, with long-term dynamic assessment throughout diagnosis and treatment rather than a one-time check at the start of therapy.

The modifiable risk factors identified in the study also offer concrete targets. Cancer pain can be addressed with standardized analgesic protocols, anemia can be monitored and corrected where clinically appropriate, and poor appetite can trigger nutritional support before cachexia takes hold. Each of these interventions is grounded in existing supportive-care guidelines, and each plausibly interrupts one of the converging pathways that produce severe fatigue. For a disease like locally advanced cervical cancer, where treatment itself, whether chemoradiation, platinum-based chemotherapy, or newer immunotherapies and anti-angiogenic agents, imposes a heavy physiological toll, the cumulative benefit of aggressively managing these secondary conditions could be substantial for patients’ quality of life.

Cervical cancer remains a major global health challenge, with GLOBOCAN 2022 estimates placing it among the leading causes of cancer incidence and mortality worldwide, and China bearing a significant share of the burden. As survival improves through combined modality therapy and emerging systemic agents, the spotlight is shifting toward survivorship and the long-term symptoms that erode patients’ daily functioning. This study adds to a growing body of work showing that fatigue is not a trivial side effect but a multifactorial syndrome intertwined with tumor biology, treatment toxicity, and the quality of supportive care. Whether Buzhong-Yiqi ultimately earns a place in evidence-based fatigue management will depend on prospective trials, but the message that half of these patients endure moderate-to-severe exhaustion, and that much of it may be preventable, is one that oncology teams everywhere cannot afford to ignore.

Subject of Research: Prevalence, risk factors, and management of moderate-to-severe cancer-related fatigue in locally advanced cervical squamous cell carcinoma, including its association with Buzhong-Yiqi use

Article Title: Prevalence and independent influencing factors of moderate-to-severe cancer-related fatigue (CRF) and its association with Buzhong-Yiqi (BZYQ) use among patients with locally advanced cervical squamous cell carcinoma (LACSCC): a retrospective observational study using propensity-score weighting (PSW) logistic regression model

Article References: Li, C., Luo, Z., Tian, L., Deng, W., Pang, Q., Bentley, G. T., Luo, Y., & Xie, K. (2026). Prevalence and independent influencing factors of moderate-to-severe cancer-related fatigue (CRF) and its association with Buzhong-Yiqi (BZYQ) use among patients with locally advanced cervical squamous cell carcinoma (LACSCC): a retrospective observational study using propensity-score weighting (PSW) logistic regression model. Supportive Care in Cancer, 34(11), Article 1084. https://doi.org/10.1007/s00520-026-11335-0

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11335-0

Keywords: cancer-related fatigue, cervical cancer, Buzhong-Yiqi, Traditional Chinese Medicine, propensity-score weighting, supportive care, anemia, cancer pain, ECOG performance status, chemoradiation, quality of life, retrospective study

The trial enrolled 132 breast cancer patients who were undergoing chemotherapy and who already suffered from sleep disturbances. Participants were randomly assigned to one of two groups. The intervention group received a twelve-week anti-inflammatory dietary education program built around the energy-adjusted dietary inflammatory index, or E-DII, a scoring system that quantifies the inflammatory potential of a person’s diet based on their intake of dozens of nutrients and food components. The control group continued with usual care. Sleep quality was assessed at baseline and again at twelve weeks using the Pittsburgh Sleep Quality Index, a widely validated questionnaire that captures everything from how long it takes to fall asleep to how often sleep is interrupted and how rested people feel in the morning.

The results were striking. In the completer analysis, which included the 116 participants, or 87.9 percent, who finished the twelve-week assessment, the proportion of patients still experiencing significant sleep disturbance, defined as a PSQI score of eight or higher, fell to 49.2 percent in the dietary education group. In the control group, the figure remained at 78.9 percent, a difference the authors report as highly statistically significant. In other words, roughly half of the women who learned to eat in an anti-inflammatory way no longer met the threshold for disturbed sleep by the end of the study, compared with fewer than a quarter of those who did not receive the education.

The continuous data reinforce that headline finding. Using linear mixed-effects models under the intention-to-treat principle, the researchers calculated that the intervention group achieved a greater reduction in PSQI scores than controls, with a beta coefficient of minus 2.10 and a 95 percent confidence interval spanning minus 3.01 to minus 1.18. A drop of more than two points on the PSQI is clinically meaningful, reflecting improvements across multiple dimensions of sleep rather than a single narrow measure. The intervention group also showed a significantly lower E-DII score, confirming that the education program genuinely changed what participants ate, shifting their diets toward components associated with reduced systemic inflammation.

Perhaps the most compelling evidence comes from the blood. Levels of interleukin-1 beta, interleukin-6, and C-reactive protein, all well-established markers of systemic inflammation, fell significantly in the intervention group, while interleukin-10, an anti-inflammatory cytokine, rose. All of these changes reached statistical significance. This biomarker profile matters because it links the behavioral intervention to a plausible biological mechanism. Sleep regulation is intimately entwined with the immune system; cytokines such as interleukin-1 beta and interleukin-6 are not merely markers of inflammation but active participants in the physiological signaling that governs sleep and wakefulness. When inflammatory signaling runs hot, sleep architecture suffers, and disturbed sleep in turn feeds back into higher inflammation, creating a vicious cycle.

That cycle is particularly relevant during chemotherapy. Previous work has shown that fatigue and poor sleep quality in breast cancer patients undergoing treatment are associated with changes in inflammatory markers, and systematic reviews have documented that sleep disturbances affect a large share of breast cancer survivors, often persisting for years after diagnosis. Chemotherapy itself can provoke inflammatory responses, and the psychological weight of cancer treatment adds further fuel. A dietary approach that measurably lowers inflammatory load therefore offers a rationale that goes beyond correlation. The Jiangnan University team had earlier reported cross-sectional evidence suggesting that inflammation may mediate the association between a pro-inflammatory diet and sleep disturbance in breast cancer patients, and the new trial was designed to test that hypothesis prospectively.

The intervention’s design is notable for its pragmatism. Rather than prescribing a rigid meal plan, the program educated patients on the principles of the dietary inflammatory index, teaching them which foods and nutrients push the index upward, such as those typical of highly processed, energy-dense eating patterns, and which pull it downward, including components abundant in Mediterranean-style diets rich in vegetables, fruit, whole grains, and unsaturated fats. Prior observational studies have repeatedly linked Mediterranean-style eating and higher diet quality to better sleep, and randomized trials in other populations, including overweight men with chronic insomnia symptoms and women with type 2 diabetes following the DASH diet, have reported sleep benefits from dietary change. The new study extends this evidence into the demanding context of active cancer treatment, where appetite changes, nausea, and fatigue make dietary modification especially challenging.

Quality of life improved alongside sleep. The intervention group showed a significantly greater gain in overall quality of life, measured with a validated breast cancer-specific instrument, with a beta of 14.07 and a confidence interval of 8.61 to 19.52. This is not a trivial side benefit. Poor sleep during chemotherapy is linked to worse fatigue, mood disturbance, and treatment tolerance, and improving it can ripple through nearly every aspect of a patient’s daily functioning. The fact that a dietary education program, delivered without drugs and without intensive clinical monitoring, produced simultaneous improvements in sleep, inflammation, and quality of life suggests a low-cost, scalable adjunct to standard supportive care.

Certain caveats deserve attention. The completer analysis of the sleep disturbance proportions included only participants who finished the study, which can introduce bias if dropouts differ systematically between groups, although the intention-to-treat models for continuous outcomes mitigate this concern. The twelve-week follow-up cannot say whether benefits persist after the education program ends or after chemotherapy concludes. And because the intervention combined education with dietary change, the trial cannot fully disentangle the effect of knowledge from the effect of the diet itself. The authors also note that raw data are available upon reasonable request, and the trial was prospectively registered with the Chinese Clinical Trial Registry, both markers of methodological transparency.

Even with those limitations, the study adds an important piece to a rapidly growing picture of diet as a modifiable lever on sleep health. Systematic reviews have connected pro-inflammatory dietary patterns to poorer sleep quality, duration, and timing, and anti-inflammatory diets have been shown to lower inflammatory markers in randomized trials across adult populations. For the millions of women worldwide who face breast cancer, a disease whose global burden continues to climb according to the latest GLOBOCAN estimates, the message from this trial is quietly revolutionary: the plate, not just the pharmacy, may be part of the answer to the sleepless nights of chemotherapy. Larger and longer trials will be needed to confirm durability and to identify which patients benefit most, but the trial, funded by the National Natural Science Foundation of China and conducted under the Declaration of Helsinki with informed consent from all participants, makes a strong case that teaching patients to eat anti-inflammatorily is a worthwhile, evidence-based investment in their rest and recovery.

Subject of Research: Effects of anti-inflammatory dietary education on sleep disturbances and inflammatory biomarkers in breast cancer patients undergoing chemotherapy

Article Title: Effects of anti-inflammatory dietary education on sleep disturbances among patients with breast cancer undergoing chemotherapy: A randomized controlled trial

Article References: Cheng, L., Huang, Z., He, J., Cheng, X., Wang, Y., Lin, X., Miao, X., Wang, R., & Xia, S. (2026). Effects of anti-inflammatory dietary education on sleep disturbances among patients with breast cancer undergoing chemotherapy: A randomized controlled trial. Supportive Care in Cancer, 34(11), Article 1082. https://doi.org/10.1007/s00520-026-11332-3

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11332-3

Keywords: breast cancer, chemotherapy, sleep disturbance, anti-inflammatory diet, dietary inflammatory index, inflammation, randomized controlled trial, Pittsburgh Sleep Quality Index, quality of life, cytokines, nutritional education, supportive care

The study was anchored in the Compassion Fatigue-Satisfaction Model, a framework first developed in the 1990s that treats caregiving as a double-edged enterprise. According to this model, professionals who sustain empathetic relationships with patients experience two simultaneous outcomes. The first is compassion satisfaction, the positive reinforcement and sense of meaning derived from helping people recover. The second is compassion fatigue, an umbrella term that encompasses both burnout, characterized by emotional exhaustion and depersonalization, and secondary traumatic stress, the emotional residue of witnessing suffering. The model predicts that these constructs jointly determine the caregiver’s overall quality of life, and it was precisely this interaction that the Ghanaian research team set out to measure in a real-world, resource-constrained clinical environment.

Between February and June 2025, the researchers surveyed nurses in the chronic care settings of a tertiary teaching hospital, a facility chosen for its high volume of complex cases and prolonged patient admissions. The target population comprised roughly 650 nurses, and a priori power analysis using G*Power indicated that 360 participants would be needed to detect a small-to-moderate effect in the mediation model. In the end, 269 nurses completed and returned the questionnaires, a response rate of 74.7 percent. The sample skewed young and female: 46.5 percent of respondents were between 20 and 35 years old, 74.3 percent were women, and more than half had five or fewer years of experience. Notably, 76.6 percent reported working 40 hours or more per week, a figure that underscores the sheer volume of clinical time these nurses devote to their patients.

The measurement instruments were rigorous and well validated. Burnout was assessed with an adapted version of the Maslach Burnout Inventory, a 21-item instrument that scores three dimensions: emotional exhaustion, depersonalization, and personal accomplishment. Compassion satisfaction was measured with the Professional Quality of Life Scale Version 5, and quality of life was captured with the single-item overall measure from the World Health Organization Quality of Life instrument, WHOQOL-BREF. After a pre-test, the scales showed respectable internal consistency, with Cronbach’s alpha values of 0.78 for the burnout inventory, 0.74 for the ProQoL, and 0.82 for the WHOQOL measure. Data were analyzed in SPSS version 27, with Pearson correlations used to map the bivariate relationships and Hayes’ PROCESS macro, Model 5, used for the moderated mediation analysis. Indirect effects were tested with 5,000 bootstrap resamples and bias-corrected 95 percent confidence intervals, a technique that provides robust estimates without relying on assumptions of normality.

The descriptive results painted a nuanced portrait. The composite mean for compassion satisfaction was 42.43 on a scale where 42 or more indicates a high level, suggesting that these nurses genuinely derive meaning and pleasure from their work. Yet the burnout scores told a parallel story of strain: emotional exhaustion averaged 18.99, depersonalization 11.35, and personal accomplishment 32.34, all indicating moderate levels of burnout. Overall quality of life came in at 2.73 on a five-point scale, a moderate rating that leaves considerable room for improvement. In other words, the same workforce that reports high satisfaction from helping patients also reports meaningful exhaustion and detachment, a combination the authors describe as particularly concerning given burnout’s documented links to turnover, absenteeism, and degraded patient care.

The correlation analysis sharpened the picture considerably. Compassion satisfaction was significantly and negatively correlated with emotional exhaustion and depersonalization, and positively correlated with personal accomplishment and quality of life. Emotional exhaustion, in turn, correlated negatively with quality of life. Interestingly, age showed no significant correlation with any of the study variables on its own, a null result that makes the moderation findings that followed all the more intriguing. The pattern of associations is consistent with the idea that compassion satisfaction functions as a psychological resource, buffering nurses against the corrosive effects of chronic caregiving stress, while emotional exhaustion acts as a pathway through which that resource is depleted.

The mediation models provided the study’s most technically significant contribution. In the first model, compassion satisfaction significantly predicted emotional exhaustion, accounting for approximately 6.65 percent of its variance, with a standardized coefficient of negative 0.3020. In the second model, predicting quality of life, the overall fit was substantial: the model explained 23.27 percent of the variance in nurses’ quality of life. Compassion satisfaction exerted a significant positive effect on quality of life, while emotional exhaustion exerted a significant negative effect. Crucially, the indirect path from compassion satisfaction through emotional exhaustion to quality of life was significant, with a bootstrap confidence interval that excluded zero, confirming that emotional exhaustion partially mediates the relationship. Higher compassion satisfaction reduces emotional exhaustion, and reduced exhaustion in turn improves quality of life.

Age emerged as a moderator with a clear directional pattern. The interaction between compassion satisfaction and age was statistically significant, and the conditional effects showed that the positive impact of compassion satisfaction on quality of life was strongest among the youngest nurses, with an effect of 0.1196 for those aged 20 to 35, weakening to 0.0989 for those aged 35 to 50 and 0.0576 for those above 50. The effect remained significant in every age band, but its magnitude declined steadily with age. The authors suggest this may reflect accumulated career experience: older nurses have developed coping strategies and emotional calluses that make their well-being less dependent on the daily rewards of compassionate care, whereas younger nurses, who dominate this workforce, lean more heavily on those rewards to sustain their quality of life.

The findings carry practical weight for health systems far beyond Ghana. Because compassion satisfaction is modifiable, the authors argue, it should be treated not merely as a personal resource but as a managerial priority with measurable outcomes in nurse performance and health system efficiency. Interventions might include supportive work environments, regular recognition and rewards for compassionate care, professional development opportunities, stress management programs, and counseling services. Given that more than three-quarters of the surveyed nurses worked 40 or more hours per week, flexible scheduling and shift rotations could also blunt the negative effects of long hours. And because the protective effect of compassion satisfaction is strongest in younger nurses, compassion-focused interventions may need to be tailored by age group, with early-career staff likely to benefit most from structured support, mentorship, and opportunities for meaningful patient engagement.

The study’s limitations are worth noting. Its cross-sectional design prevents causal inference, self-reported measures are vulnerable to social desirability bias, and the single-hospital setting, though large and diverse in its units, limits generalizability to other healthcare contexts. The response rate, while respectable, fell short of the powered target sample. Still, the research adds an important piece to a growing global evidence base on professional quality of life in nursing, and it does so in a setting where high patient-to-nurse ratios and the demands of chronic illness care intensify every occupational stressor. As health systems worldwide grapple with nursing shortages and post-pandemic burnout, the message from these Ghanaian chronic care wards is clear: protecting the joy of caring may be one of the most effective ways to protect the caregivers themselves, and through them, the quality and safety of the care that patients receive.

Subject of Research: Burnout, compassion satisfaction and quality of life among nurses in chronic care settings in Ghana

Article Title: The Cost of Caring: Burnout, Compassion Satisfaction and Quality of Life Among Nurses in Chronic Care Settings in Ghana

Article References: Poku, C. A., Asante, J. K., Kyei‐Fram, F., Oppong, P., Acquah, A. A. B., Brown, S. A., & Hagan, D. (2026). The Cost of Caring: Burnout, Compassion Satisfaction and Quality of Life Among Nurses in Chronic Care Settings in Ghana. Nursing Open, 13(10), Article e70923. https://doi.org/10.1002/nop2.70923

Image Credits: AI Generated

DOI: 10.1002/nop2.70923

Keywords: nursing, burnout, compassion satisfaction, quality of life, chronic care, Ghana, emotional exhaustion, mediation analysis, occupational stress, Maslach Burnout Inventory, ProQoL, nurse well-being

The research, led by Gabriela Lampart of the Doctoral School of Medical and Health Sciences at Jagiellonian University Medical College in Krakow, followed adult transplant recipients at a single center, the Department of Hematology at University Hospital in Krakow. Patients completed validated questionnaires at three carefully chosen timepoints: within twenty-four hours after the infusion of donor stem cells, at one month, and at six months. Fatigue was measured with two complementary instruments, the Functional Assessment of Chronic Illness Therapy-Fatigue scale, known as FACIT-F, and the Brief Fatigue Inventory, or BFI. Quality of life was captured with the Functional Assessment of Cancer Therapy-Bone Marrow Transplant questionnaire, FACT-BMT, which spans physical, social and family, emotional, and functional well-being alongside transplant-specific concerns.

Of forty-one patients enrolled in the parent longitudinal project, twenty-eight completed all three early assessments and formed the primary complete-case cohort. The remaining thirteen were excluded from the primary analysis because of death before the six-month follow-up or loss to follow-up, including changes of treatment center. The cohort was predominantly female, with seventeen women and eleven men, and was split roughly evenly between younger and older patients relative to the sample mean age of forty-eight years. Importantly, no statistically significant baseline differences were detected between patients who later developed graft-versus-host disease and those who did not, although the authors caution that such comparisons in a small sample are descriptive rather than definitive.

Graft-versus-host disease, or GVHD, arises when donor immune cells recognize the recipient’s tissues as foreign and mount an attack. It is one of the most frequent and clinically consequential complications of allo-HSCT. In this study, exactly half of the cohort, fourteen patients, developed GVHD during early follow-up. Six had acute disease and eight had chronic disease. The skin was the most commonly affected organ, involved in eight patients, followed by the gastrointestinal tract in four and the liver in two. Treatment responses were documented with the help of the eGVHD application developed at UZ Leuven in Belgium, and patients were classified as responders if they achieved a complete or partial response, and non-responders otherwise. Eight patients responded to therapy while six did not.

The statistical architecture of the study rested on linear mixed-effects models, a technique well suited to repeated measurements within the same individuals because it accounts for the fact that observations from one patient are correlated over time. The results were strikingly consistent. Quality of life improved significantly over the six months, and fatigue declined in parallel, with all time effects reaching statistical significance at p less than 0.001. But overlaying this general recovery was a persistent divide: patients who developed GVHD reported consistently worse outcomes at every timepoint. The GVHD effect was highly significant for FACT-BMT, BFI, and FACIT-F alike, and, notably, the time-by-GVHD interactions were not significant, indicating that the two groups recovered along broadly parallel trajectories rather than diverging over time.

The magnitude of the differences is clinically meaningful. At the first assessment, patients without GVHD reported a mean FACT-BMT score of 96.4, rising to 123.6 by six months. GVHD responders started far lower at 72.4 and reached only 92.4, while non-responders began at 49.2 and climbed to just 74.3. Fatigue told the mirror-image story. On the BFI, where higher scores indicate greater fatigue and interference with daily life, non-responders scored 8.5 at the outset and still 7.0 at six months, compared with 6.1 falling to 4.7 among patients free of GVHD. On the FACIT-F, where higher scores mean less fatigue, non-responders languished at 9.7 initially and 16.3 at six months, against 23.3 and 30.4 in the no-GVHD group.

Perhaps the most powerful finding concerns the relationship between fatigue and quality of life itself. Across all eighty-four pooled observations, FACT-BMT scores correlated negatively with BFI at r equal to minus 0.813 and positively with FACIT-F at r equal to 0.857, both highly significant. The two fatigue instruments were almost perfectly inversely correlated, at r equal to minus 0.957, confirming they capture the same underlying construct from opposite directions. Crucially, fatigue remained an independent correlate of quality of life in multivariable models that adjusted for time, GVHD status, sex, and age group. In the model using BFI, each unit increase in fatigue was associated with a drop of roughly eight points in FACT-BMT, while GVHD itself carried an independent penalty of nearly twenty-four points.

Within the GVHD subgroup, an exploratory analysis revealed that response to treatment further stratified outcomes. Responders enjoyed significantly better quality of life and lower fatigue than non-responders, with p-values of 0.016 for FACT-BMT, below 0.001 for BFI, and 0.017 for FACIT-F. Again, the absence of significant time-by-response interactions suggested that these differences were sustained rather than widening or narrowing. The authors are careful to frame this comparison as hypothesis-generating, since treatment response was defined during follow-up and the subgroup was small. Subscale analyses added nuance: physical and functional well-being showed the largest deficits associated with GVHD, emotional well-being was also significantly affected, while social and family well-being appeared relatively preserved, perhaps reflecting the buffering role of social support during severe illness.

The study’s limitations deserve honest attention. The single-center design and small sample constrain generalizability, and the complete-case approach may have introduced selection bias, because patients who died, relapsed, or deteriorated clinically were less likely to complete all assessments. Missing data in this setting may be informative rather than random, meaning the observed recovery could be overestimated relative to an unselected transplant population. Sensitivity analyses including all available early assessments showed consistent directions of association, which strengthens confidence, but the authors also note that there was no true pre-transplant baseline, since the first measurement came after conditioning therapy, when symptom burden was already substantial. Because GVHD status was defined cumulatively during follow-up, early group differences may partly reflect pre-existing vulnerability rather than the direct effects of the disease itself.

Even with these caveats, the clinical implications are clear and actionable. The authors argue that fatigue should be treated not as an inevitable side effect to be endured, but as a potentially modifiable target for supportive care. Candidate interventions include individualized exercise-based rehabilitation, physiotherapy, gradual physical activity programs, psychosocial support, fatigue education, sleep optimization, nutritional support, and systematic management of contributing conditions such as pain, anemia, infections, endocrine dysfunction, depression, and anxiety. In patients with GVHD, fatigue management must be woven into GVHD treatment itself, adapted to immunosuppressive regimens, infection risk, and functional limitations. Structured patient-reported outcome monitoring, reviewed systematically by the care team and linked to timely interventions, could transform how the most vulnerable months after transplantation are managed. As the parent project extends follow-up to twenty-four months, larger multicenter studies will be needed to confirm whether early fatigue trajectories can serve as warning signs of poor GVHD control, and whether fatigue-directed interventions can genuinely bend the quality-of-life curve for transplant survivors.

Subject of Research: Fatigue and quality of life dynamics during the first six months after allogeneic hematopoietic stem cell transplantation and the impact of graft-versus-host disease

Article Title: Fatigue and quality of life in the early phase after allogeneic hematopoietic stem cell transplantation: dynamics and the impact of graft-versus-host disease

Article References: Lampart, G., Kubarek, M., Gniadek, A., & Piątkowska-Jakubas, B. (2026). Fatigue and quality of life in the early phase after allogeneic hematopoietic stem cell transplantation: dynamics and the impact of graft-versus-host disease. Supportive Care in Cancer, 34(11), Article 1081. https://doi.org/10.1007/s00520-026-11220-w

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11220-w

Keywords: allogeneic hematopoietic stem cell transplantation, graft-versus-host disease, fatigue, quality of life, patient-reported outcomes, FACT-BMT, FACIT-F, Brief Fatigue Inventory, supportive care, hematological malignancies, longitudinal study, bone marrow transplantation

The headline finding is the sheer variability of the numbers. Among established long-term survivor cohorts, chronic pain prevalence ranged from 8.6 percent to 67.1 percent, a nearly eightfold spread that reflects differences in cancer type, treatment regimens, time since treatment, and how pain itself was measured. Head and neck cancer survivors, breast cancer survivors treated with surgery and radiotherapy, and patients who received neurotoxic chemotherapy all feature prominently in the evidence base. The authors caution that this heterogeneity is not simply statistical noise; it signals that chronic pain after cancer is not one condition but a family of conditions with different biological origins and different trajectories.

To understand why pain persists long after tumors are removed, the review turned to modern mechanistic classifications of chronic pain. Neuropathic pain, caused by direct damage or disease affecting the somatosensory nervous system, emerged as the most frequently reported mechanism across the included studies. This is biologically plausible: surgical dissection can sever peripheral nerves, radiation can injure nerve plexuses, and chemotherapeutic agents such as taxanes and platinum compounds are well known for causing peripheral neuropathy. In colorectal cancer survivors followed for up to eleven years in population-based registry studies, chemotherapy-induced neuropathy was associated with measurably worse quality of life, and in head and neck populations, radiation-induced nervous system complications were linked to persistent pain syndromes.

But the review also highlights a more controversial and scientifically intriguing category: nociplastic pain. Introduced into the International Classification of Diseases through the International Association for the Study of Pain’s ICD-11 framework, nociplastic pain arises from altered nociceptive processing despite no clear evidence of actual or threatened tissue damage or of a lesion in the somatosensory system. Some survivor populations in the review showed symptom profiles consistent with this mechanism, including patterns suggestive of central sensitization, in which the central nervous system becomes hyperexcitable and amplifies pain signals. Breast cancer survivor cohorts assessed with instruments such as the Central Sensitization Inventory showed that a subset of patients experience pain that cannot be explained by nerve damage or tissue injury alone.

Here the authors insert an important scientific caveat. Most mechanistic classifications in the reviewed studies were based on screening instruments and symptom questionnaires rather than diagnostic confirmation through quantitative sensory testing or other objective measures. Central sensitization, in particular, remains a construct that is easy to describe but difficult to verify. The certainty of evidence across the three outcome domains of prevalence, mechanism, and psychological impact was evaluated using the GRADE framework, and the authors are candid that the mechanistic evidence remains suggestive rather than definitive. This is a call to the research community: the field needs rigorous phenotyping studies that combine psychophysical testing, imaging, and longitudinal follow-up to move beyond symptom-based surrogates.

The psychological toll of persistent pain emerges as the review’s most consistent finding. Across the included studies, cancer survivors with chronic pain reported higher levels of anxiety, more severe depressive symptoms, greater emotional distress, and poorer quality of life than pain-free survivors. This comorbidity is not incidental. Decades of research on depression and pain comorbidity show that the two conditions share neurotransmitter pathways and amplify each other in a vicious cycle: pain disrupts sleep, sleep loss lowers pain thresholds and worsens mood, and depression reduces the motivation and energy needed for rehabilitation and self-management. Studies in the review found that post-traumatic stress symptoms arising from multiple cancer-related stressors predicted chronic pain, and that pain catastrophizing, the tendency to ruminate and magnify pain, was elevated in survivors with refractory postsurgical pain.

The functional consequences extend beyond mood. Research on working-age survivors has linked chronic pain to reduced health-related quality of life and to difficulties maintaining employment, a burden with obvious economic and social dimensions. For head and neck cancer survivors, pain often coexists with difficulties in swallowing, speaking, and shoulder function, compounding the impact on daily life. In breast cancer populations, persistent pain after treatment has been described as an underreported burden, with many patients never raising the issue during follow-up visits and clinicians rarely asking. The review’s implications section is direct: survivors should report ongoing pain and emotional symptoms, and survivorship care should include routine assessment of both.

Methodologically, the review is a model of transparency. The authors searched five major databases, PubMed, Scopus, Web of Science, Embase, and PsycINFO, registered their protocol prospectively in PROSPERO, appraised methodological quality with the Joanna Briggs Institute critical appraisal tools, and followed the PRISMA 2020 reporting guidelines. The included studies were predominantly cross-sectional and cohort designs covering a wide range of malignancies, from melanoma and testicular cancer to colorectal, breast, lung, and prostate cancers. No new primary data were generated; the analysis is entirely a synthesis of previously published work, with supporting data available in the article’s supplementary materials.

What should clinicians and patients take away from this body of evidence? First, chronic pain after cancer is common enough that it should be screened for systematically, not discovered only when a patient volunteers the information. The American Society of Clinical Oncology has long had a clinical practice guideline for managing chronic pain in adult cancer survivors, yet the review suggests that long-term care strategies remain lacking in practice. Second, because the mechanisms differ, treatment should differ: neuropathic pain may respond to different classes of medication than nociplastic pain, which often benefits from exercise, cognitive behavioral approaches, and centrally acting strategies. Multidimensional pain assessment, covering sensory qualities, psychological state, sleep, and function, is the practical corollary of the review’s mechanistic message.

Finally, the review identifies where science must go next. Stronger mechanistic research is needed to distinguish reliably between neuropathic, nociceptive, and nociplastic contributions in individual patients, and longitudinal studies should track how pain phenotypes evolve from the end of treatment into long-term survivorship. Emerging tools, including wearable devices capable of continuously monitoring pain-related parameters, may eventually help predict which patients are at highest risk before pain becomes entrenched. For now, the message for the growing global population of cancer survivors is clear: pain that persists after treatment is a medical condition in its own right, it is strongly linked to mental health, and it deserves the same systematic attention that surveillance for cancer recurrence already receives.

Subject of Research: Prevalence, mechanisms, and psychological outcomes of chronic pain in cancer survivors

Article Title: Prevalence, mechanisms, and psychological outcomes of chronic pain in cancer survivors: a systematic review with narrative synthesis

Article References: Myrzabay, Z., & Viderman, D. (2026). Prevalence, mechanisms, and psychological outcomes of chronic pain in cancer survivors: a systematic review with narrative synthesis. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02138-7

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02138-7

Keywords: cancer survivors, chronic pain, neuropathic pain, nociplastic pain, central sensitization, psychological outcomes, quality of life, systematic review, chemotherapy-induced neuropathy, survivorship care, depression, anxiety